ANGLE plc (GB:AGL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ANGLE plc has unveiled promising new data at the AACR Special Conference, highlighting the development of a Parsortix-based HER2 assay kit for metastatic breast cancer patients. This innovative solution allows for the continuous assessment of HER2 status, potentially identifying patients who could benefit from targeted therapies. The study revealed significant cases where HER2 status changed over time, underscoring the potential of this assay in personalized cancer treatment.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue